Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

345
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
345
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

250
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
250
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

205
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
205
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

376
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
376
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

236
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-modal AI for comprehensive breast cancer prognostication.

Nature communications·2026
Same author

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.

Clinical breast cancer·2025
Same author

The Tailored Biosimilar Approach: Expectations and Requirements.

Drugs·2025
Same author

Tofersen for SOD-1-associated amyotrophic lateral sclerosis.

The Lancet. Neurology·2024
Same author

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Biosimilars: Here and Now.

Steven J Lemery1, Francisco J Esteva1, Martina Weise1

  • 1From the U.S. Food and Drug Administration, Silver Spring, MD; New York University Clinical Cancer Center, New York, NY; Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 2, 2016
PubMed
Summary
This summary is machine-generated.

The Biologics Price Competition and Innovation Act (BPCI Act) created a pathway for biosimilar products, promoting competition and patient access to biologics. Demonstrating biosimilarity requires extensive characterization and targeted clinical data, not necessarily for every indication.

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

2.0K

Area of Science:

  • Biotechnology
  • Regulatory Science
  • Pharmacoeconomics

Background:

  • The Biologics Price Competition and Innovation Act (BPCI Act) was enacted in 2010.
  • This act established an abbreviated regulatory pathway for biosimilar and interchangeable biological products.
  • Biosimilars aim to increase competition and patient access to biologic therapies.

Purpose of the Study:

  • To define the regulatory framework for biosimilar product approval in the United States.
  • To explain the scientific standards for demonstrating biosimilarity.
  • To highlight the potential benefits of the biosimilar pathway for healthcare.

Main Methods:

  • The BPCI Act defines biosimilarity as high similarity with no clinically meaningful differences in safety, purity, and potency.
  • Regulatory review employs a totality-of-the-evidence approach.
  • Extrapolation of data across indications is permitted with scientific justification.

Main Results:

  • The biosimilar pathway facilitates market entry of lower-cost biological products.
  • Demonstrating biosimilarity relies on comprehensive analytical and clinical data.
  • Extrapolation can streamline development and conserve resources.

Conclusions:

  • The BPCI Act promotes competition, potentially lowering healthcare costs and improving patient access to biologics.
  • The regulatory framework emphasizes rigorous scientific evaluation while allowing for efficient product development.
  • The biosimilar pathway is crucial for sustainable access to innovative therapies, particularly in areas like oncology.